A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisAlessandro M. Vannucchi, Jason Gotlib, F. Cervantes et al.|Haematologica|2015Cited by 252
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studiesVikas Gupta, Srđan Verstovšek, Claire Harrison et al.|Haematologica|2016Cited by 85